- Home
- XERS vs DIN Comparison
XERS vs DIN Comparison
Compare XERS & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- DIN
- Stock Information
- Founded
- XERS 2005
- DIN 1958
- Country
- XERS United States
- DIN United States
- Employees
- XERS N/A
- DIN N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- DIN Restaurants
- Sector
- XERS Health Care
- DIN Consumer Discretionary
- Exchange
- XERS Nasdaq
- DIN Nasdaq
- Market Cap
- XERS 444.0M
- DIN 462.0M
- IPO Year
- XERS 2018
- DIN 1991
- Fundamental
- Price
- XERS $3.09
- DIN $32.98
- Analyst Decision
- XERS Buy
- DIN Buy
- Analyst Count
- XERS 3
- DIN 8
- Target Price
- XERS $4.87
- DIN $40.83
- AVG Volume (30 Days)
- XERS 1.9M
- DIN 532.3K
- Earning Date
- XERS 11-08-2024
- DIN 11-06-2024
- Dividend Yield
- XERS N/A
- DIN 6.19%
- EPS Growth
- XERS N/A
- DIN 25.34
- EPS
- XERS N/A
- DIN 6.02
- Revenue
- XERS $187,361,000.00
- DIN $813,838,000.00
- Revenue This Year
- XERS $20.35
- DIN N/A
- Revenue Next Year
- XERS $16.14
- DIN $0.60
- P/E Ratio
- XERS N/A
- DIN $5.47
- Revenue Growth
- XERS 22.72
- DIN N/A
- 52 Week Low
- XERS $1.69
- DIN $28.25
- 52 Week High
- XERS $3.64
- DIN $52.05
- Technical
- Relative Strength Index (RSI)
- XERS 49.74
- DIN 51.10
- Support Level
- XERS $2.82
- DIN $31.50
- Resistance Level
- XERS $3.12
- DIN $37.20
- Average True Range (ATR)
- XERS 0.18
- DIN 1.68
- MACD
- XERS -0.03
- DIN -0.16
- Stochastic Oscillator
- XERS 32.93
- DIN 42.24
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About DIN Dine Brands Global Inc.
Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations, and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.